Shares of COLLPLANT HOLDI/S (NASDAQ:CLGN) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a one year consensus price objective of $7.00 for the company and are expecting that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also given COLLPLANT HOLDI/S an industry rank of 80 out of 256 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded shares of COLLPLANT HOLDI/S from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a research note on Thursday, April 11th.
COLLPLANT HOLDI/S (NASDAQ:CLGN) last posted its quarterly earnings data on Monday, April 1st. The company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.74. COLLPLANT HOLDI/S had a negative net margin of 24.19% and a negative return on equity of 3.27%. The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $19.35 million. On average, equities research analysts expect that COLLPLANT HOLDI/S will post -1.62 earnings per share for the current year.
About COLLPLANT HOLDI/S
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe.
Recommended Story: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.